

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2001/0034330	10/25/01	Kensil	514	44	01/12/01
	A2	2003/0148261	08/07/03	Fikrig <i>et al.</i>	435	5	03/11/02
	A3	2003/0162190	08/28/03	Gorenstein <i>et al.</i>	435	6	08/06/02
	A4	2003/0162216	08/28/03	Gold <i>et al.</i>	435	6	02/27/03
	A5	2003/0180329	09/25/03	Monath <i>et al.</i>	424	218.1	01/15/03
	A6	2003/0186906	10/02/03	Schlingensiepen <i>et al.</i>	514	44	10/31/02
	A7	2003/0228327	12/11/03	Lasher <i>et al.</i>	424	188.1	11/04/02
	A8	2004/0037848	02/26/04	Audonnet <i>et al.</i>	424	199.1	02/26/03
	A9	2004/0052818	03/18/04	Heinz <i>et al.</i>	424	202.1	10/23/03
	A10	2005/0002968	01/06/05	Monath <i>et al.</i>	424	218.1	02/27/04
	A11	2005/0031641	02/10/05	Loosmore <i>et al.</i>	424	199.1	10/06/03
	A12	2005/0053624	03/10/05	Arroyo <i>et al.</i>	424	218.1	11/17/03
	A13	2005/0163804	07/28/05	Chang	424	218.1	07/06/04
	A14	2005/0164170	07/28/05	Despres <i>et al.</i>	435	5	10/04/04
	A15	4,447,356	05/08/84	Oliver <i>et al.</i>	530	327	06/04/82
	A16	4,500,512	02/19/85	Barne	424	218.1	05/05/82
	A17	4,810,492	11/19/86	Fujita <i>et al.</i>	424	4186.1	03/07/89
	A18	5,218,088	06/08/93	Gorenstein <i>et al.</i>	536	25.34	11/02/89
	A19	5,220,007	06/15/93	Pederson <i>et al.</i>	536	523.1	02/19/92
	A20	5,270,163	12/14/93	Gold <i>et al.</i>	435	6	08/17/92
	A21	5,284,760	02/08/94	Feinstone <i>et al.</i>	435	491.1	09/23/91
	A22	5,354,670	10/11/94	Nickoloff <i>et al.</i>	435	491.53	08/11/93
	A23	5,366,878	11/22/94	Pederson <i>et al.</i>	435	491.3	03/24/93

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A24	5,389,514	02/14/95	Taylor	435	46	08/28/92
	A25	5,397,698	03/14/95	Goodman <i>et al.</i>	435	6	11/02/93
	A26	5,475,096	12/12/95	Gold <i>et al.</i>	536	23.1	06/10/91
	A27	5,514,774	05/07/96	Olivera <i>et al.</i>	530	324	10/19/93
	A28	5,576,302	11/19/96	Cook <i>et al.</i>	514	44	06/06/95
	A29	5,582,981	12/10/96	Toole <i>et al.</i>	435	6	04/28/94
	A30	5,587,361	12/24/96	Cook <i>et al.</i>	514	44	06/06/95
	A31	5,589,340	12/31/96	Olivera <i>et al.</i>	435	6	06/07/95
	A32	5,591,821	01/07/97	Olivera <i>et al.</i>	530	324	07/16/93
	A33	5,595,972	01/21/97	Olivera <i>et al.</i>	514	13	06/07/95
	A34	5,599,797	02/04/97	Cook <i>et al.</i>	514	44	06/06/95
	A35	5,602,000	02/11/97	Hyman	435	91.1	06/23/95
	A36	5,607,923	03/04/97	Cook <i>et al.</i>	514	44	06/06/95
	A37	5,620,963	04/15/97	Cook <i>et al.</i>	514	44	06/06/95
	A38	5,633,347	05/27/97	Olivera <i>et al.</i>	530	324	06/07/95
	A39	5,635,377	06/03/97	Pederson <i>et al.</i>	435	91.3	11/18/94
	A40	5,635,488	06/03/97	Cook <i>et al.</i>	435	44	06/06/95
	A41	5,639,603	06/17/97	Dower <i>et al.</i>	435	6	11/02/93
	A42	5,639,873	06/17/97	Barascut <i>et al.</i>	536	25.3	08/04/94
	A43	5,660,985	08/26/97	Pieken <i>et al.</i>	435	6	04/27/95
	A44	5,661,134	08/26/97	Cook <i>et al.</i>	514	44	06/06/95
	A45	5,663,153	09/02/97	Hutcherson <i>et al.</i>	514	44	06/06/95
	A46	5,668,265	09/16/97	Nadeau <i>et al.</i>	536	23.1	03/12/96

25526940 1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A47	5,670,622	09/23/97	Shon <i>et al.</i>	530	324	02/15/96
	A48	5,670,637	09/23/97	Gold <i>et al.</i>	536	22.1	03/27/95
	A49	5,672,682	09/30/97	Terlau <i>et al.</i>	530	324	03/18/96
	A50	5,696,249	12/09/97	Gold <i>et al.</i>	536	23.1	03/24/95
	A51	5,705,337	01/06/98	Gold <i>et al.</i>	435	6	03/08/95
	A52	5,719,264	02/17/98	Shon <i>et al.</i>	530	324	10/07/94
	A53	5,734,041	03/31/98	Just <i>et al.</i>	536	25.31	10/20/95
	A54	5,736,148	04/07/98	Sumiyoshi <i>et al.</i>	424	218.1	05/11/95
	A55	5,739,276	04/14/98	Shon <i>et al.</i>	530	324	03/29/96
	A56	5,744,140	04/28/98	Paoletti <i>et al.</i>	424	4199.1	04/07/94
	A57	5,744,141	04/28/98	Paoletti <i>et al.</i>	424	4199.1	06/07/95
	A58	5,756,291	05/26/98	Griffin <i>et al.</i>	435	6	06/07/95
	A59	5,763,595	06/09/98	Gold <i>et al.</i>	536	22.1	06/05/95
	A60	5,780,221	07/14/98	Schumacher <i>et al.</i>	435	5	03/28/96
	A61	5,789,166	08/04/98	Bauer <i>et al.</i>	435	46	12/08/95
	A62	5,795,721	08/18/98	Rabin <i>et al.</i>	435	6	01/25/96
	A63	5,798,208	08/25/98	Crea	435	46	11/02/92
	A64	5,801,154	09/01/98	Baracchini <i>et al.</i>	514	44	04/08/97
	A65	5,804,445	09/08/98	Brasier	435	375	01/11/96
	A66	5,830,650	11/03/98	Crea	435	6	05/30/95
	A67	5,844,106	12/01/98	Seela <i>et al.</i>	536	22.1	11/06/95
	A68	5,853,984	12/29/98	Davis <i>et al.</i>	435	6	06/07/95
	A69	5,874,219	02/23/99	Rava	435	6	04/09/96

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A70	5,885,780	03/23/99	Olivera <i>et al.</i>	435	7.1	07/19/91
	A71	5,969,096	10/19/99	Shon <i>et al.</i>	530	325	06/26/98
	A72	5,990,295	11/23/99	Shon <i>et al.</i>	536	23.5	01/13/98
	A73	6,150,088	11/21/00	Chan <i>et al.</i>	435	5	04/17/98
	A74	6,171,792	01/09/01	Brent <i>et al.</i>	435	6	11/10/98
	A75	6,171,854	01/09/01	Galler <i>et al.</i>	435	320.1	04/10/98
	A76	6,180,348	01/30/01	Li	435	6	04/07/99
	A77	6,184,024	02/06/01	Lai <i>et al.</i>	435	235.1	05/27/94
	A78	6,242,246	06/06/01	Gold <i>et al.</i>	435	287.1	12/15/97
	A79	6,254,873	07/03/01	Putnak <i>et al.</i>	424	218.1	04/17/95
	A80	6,265,541	07/24/01	Olivera <i>et al.</i>	530	326	12/23/98
	A81	6,337,073	01/08/02	Niedrig <i>et al.</i>	424	218.1	07/01/99
	A82	6,346,611	02/12/02	Pagratris <i>et al.</i>	536	23.1.	07/29/99
	A83	6,369,208	04/09/02	Cole <i>et al.</i>	536	23.1	03/30/98
	A84	6,372,221	04/16/02	Mannhalter <i>et al.</i>	424	196.11	01/03/97
	A85	6,423,493	07/23/02	Gorenstein <i>et al.</i>	435	6	10/25/99
	A86	6,458,543	10/01/02	Gold <i>et al.</i>	435	6	11/28/00
	A87	6,503,715	01/07/03	Gold <i>et al.</i>	435	6	11/28/00
	A88	6,506,554	01/14/03	Chan <i>et al.</i>	435	5	01/18/00
	A89	6,514,948	02/04/03	Raz <i>et al.</i>	514	44	07/02/99
	A90	6,544,776	04/08/03	Gold <i>et al.</i>	435	287.2	08/14/00
	A91	6,551,795	04/22/03	Rubenfield <i>et al.</i>	435	69.1	02/18/99
	A92	6,576,757	06/10/03	Punnonen <i>et al.</i>	536	23.72	11/28/00

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A93	6,610,504	08/26/03	Yuan	435	15	04/10/00
	A94	6,713,616	03/30/04	Pagratiss <i>et al.</i>	536	23.1	02/23/01
	A95	6,716,629	04/06/04	Hess <i>et al.</i>	435	420	10/10/01
	A96	6,725,526	04/27/04	Lille	29	603.1	01/14/02
	A97	6,734,022	05/11/04	Hutchens <i>et al.</i>	436	173	03/15/01
	A98	6,844,165	01/18/05	Hutchens <i>et al.</i>	435	7.92	12/21/00
	A99	6,867,289	03/15/05	Gorenstein <i>et al.</i>	536	23.1	10/25/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	WO 01/60847	08/23/01	WIPO	English
	B2	WO 02/072036	09/19/02	WIPO	English
	B3	WO 02/081621	10/17/02	WIPO	English Abstract
	B4	WO 03/048184	06/12/03	WIPO	English
	B5	WO 03/061555	07/31/03	WIPO	English
	B6	WO 03/103571	12/18/03	WIPO	English
	B7	WO 04/016586	02/26/04	WIPO	English
	B8	WO 04/045529	06/03/04	WIPO	English
	B9	WO 05/042014	05/12/05	WIPO	English

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Amarzguoui <i>et al.</i> , "Tolerance for mutations and chemical modification in a siRNA," <i>Nuc. Acids Res.</i> , 31:589-595, 2003.
	C2	Anderson <i>et al.</i> , "A phylogenetic approach to following West Nile virus in Connecticut," <i>PNAS</i> , 98:12885-12889, 2001.
	C3	Arroyo <i>et al.</i> , "ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy," <i>J. Virology</i> , 78:12497-12507, 2004.
	C4	Bane <i>et al.</i> , "DNA affinity capture and protein profiling by SELDI-TOF mass spectrometry: effect of DNA methylation," <i>Nucleic Acids Research</i> , 30:e69, 2002.
	C5	Bartelma <i>et al.</i> , "Expression, Purification, and Characterization of the RNA 5'-Triphosphatase Activity of Dengue Virus Type 2 Nonstructural Protein 3," <i>Virology</i> , 299: 122-132, 2002.
	C6	Beasley and Barrett, "Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein." <i>J. Virol</i> , 76(24):13097-13100, 2002.
	C7	Beasley <i>et al.</i> , "Limited evolution of West Nile virus has occurred during its southwesterly spread in the United States," <i>Virology</i> , 309: 190-195, 2003.
	C8	Beasley <i>et al.</i> , "Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype." <i>J. Virol</i> , 296(1):17-23, 2002.
	C9	Berthet <i>et al.</i> , "Extensive nucleotide changes and deletions within the envelope glycoprotein gene of Euro-African West Nile viruses," <i>J. General Virology</i> , 78: 2293-2297, 1997.
	C10	Bhardwaj <i>et al.</i> , "Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein." <i>J. Virol</i> , 75:4002-4007, 2001.
	C11	Blitvich <i>et al.</i> , "Serologic evidence of West Nile virus infection in horses, Coahuila State, Mexico," <i>Emerg. Infect. Dis.</i> , 9: 853-856, 2003.
	C12	Braasch <i>et al.</i> , "Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design," <i>Nucleic Acids Res.</i> , 30:5150-7, 2002.
	C13	Brinton, "The molecular biology of West Nile Virus: a new invader of the western hemisphere," <i>Annu. Rev. Microbiol.</i> , 56:371-402, 2002.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

25526940.1

EXAMINER:

DATE CONSIDERED:

EXAMINER, INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C14	Brown <i>et al.</i> , "Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?" <i>J. Immunol.</i> , 156(9):3285-3291, 1996.
	C15	Burke and Monath, "Flaviviruses," <i>In</i> D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), <i>Fields virology</i> , 4th ed., vol. 1: Lippincott Williams & Wilkins, Philadelphia, Pa., 1043-1125, 2001.
	C16	Burton and Barbas, "Human antibodies from combinatorial libraries." <i>Adv. Immunol.</i> , 57:191-280, 1994.
	C17	Butrapet <i>et al.</i> , "Attenuation Markers of a Candidate Dengue Type 2 Vaccine Virus, Strain 16681 (PDK-53), Are Defined by Mutations in the 5' Noncoding Region and Nonstructural Proteins 1 and 3," <i>J. Virology</i> , 74:3011-3019, 2000.
	C18	Caplen <i>et al.</i> , "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate systems," <i>PNAS</i> , 98:9742-9747, 2001.
	C19	CDC, "Serological and molecular amplification assays for West Nile & other arboviruses," 2001.
	C20	Chambers <i>et al.</i> , "West Nile virus envelope proteins: nucleotide sequence analysis of strains differing in mouse neuroinvasiveness," <i>J. General Virology</i> , 79: 2375-2380, 1998.
	C21	Chappell <i>et al.</i> , "Site-directed Mutagenesis and Kinetic Studies of the West Nile Virus NS3 Protease Identify Key Enzyme-Substrate Interactions," <i>J. Biol. Chem.</i> , 280(4): 2896-2903, 2005.
	C22	Charrel <i>et al.</i> , "Evolutionary relationship between Old World West Nile virus strains Evidence for viral gene flow between Africa, the Middle East, and Europe," <i>Virology</i> , 315: 381-388, 2003
	C23	Chi, "Genomewide view of gene silencing by small interfering RNAs," <i>PNAS</i> , 100:6343-6, 2003.
	C24	Crill and Roehrig, "Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells." <i>J. Virol.</i> , 75(16):7769-7773, 2001.
	C25	Davis <i>et al.</i> , "Genetic variation among temporally and geographically distinct West Nile virus isolates collected in the United States, 2001 and 2002," <i>Emerg. Infect. Dis.</i> , 10(1): 160, 2004.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

25526940 1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C26	Dobler <i>et al.</i> , "Diagnosis of tick-borne encephalitis: evaluation of sera with borderline titers with the TBE-ELISA." <i>Infection</i> , 24:405-406, 1996.
	C27	Dunster <i>et al.</i> , "Attenuation of virulence of flaviviruses following passage in HeLa cells," <i>J. Gen. Vir.</i> , 71: 601-607, 1990.
	C28	Dupuis <i>et al.</i> , "Serological evidence of West Nile virus transmission, Jamaica, West Indies," <i>Emerg. Infect. Dis.</i> , 9: 860-863, 2003.
	C29	Ebel <i>et al.</i> , "Genetic and Phenotypic Variation of West Nile Virus in New York, 2000-2003," <i>Am. J. Trop. Med. Hyg.</i> , 71(4): 493-500, 2004.
	C30	Egloff <i>et al.</i> , "An RNA cap (nucleoside-2'-O-)-Methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization," <i>The EMBO Journal</i> , 21(11): 2757-2768, 2002.
	C31	Elbashir <i>et al.</i> , "Functional anatomy of siRNAs for medicating efficient RNAi in drosophilla melanogaster embryo lysate," <i>EMBO Journal</i> , 20:6877-6888, 2001.
	C32	Elbashir <i>et al.</i> , "RNA interference is mediated by 21-and 22-nucleotide RNAs," <i>Genes and Development</i> , 15:188-200, 2001.
	C33	Estrada-Franco <i>et al.</i> , "West Nile virus in Mexico: evidence of widespread circulation since July 2002," <i>Emerg. Infect. Dis.</i> , 9: 1604-1607, 2003.
no dates	C34	Fonseca <i>et al.</i> , "Flavivirus type-specific antigens produced from fusions of a portion of the E protein gene with the Escherichia coli trpE gene." <i>Am. J. Trop. Med. Hyg.</i> , 44(5):500-8, 1991.
	C35	GenBank Accession No. AF106825
	C36	GenBank Accession Number NP_041724
	C37	GenBank Accession Number U117066
	C38	GenBank Accession Number U17067
	C39	GenBank Accession Number U21055
	C40	GenBank Accession Number U21056
	C41	GenBank Accession Number X03700
	C42	GenBank Accession Number X15061

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C43	Gould <i>et al.</i> , "Evolution, epidemiology, and dispersal of flaviviruses revealed by molecular phylogenies." <i>Adv Virus Res</i> , 57:71-103, 2001.
	C44	Gritsun <i>et al.</i> , "Nucleotide and deduced amino acid sequence of the envelope gene of the Vasilchenko strain of TBE virus; comparison with other flaviviruses," <i>Virus Res</i> , 27:201-209, 2003.
	C45	Hahn <i>et al.</i> , "Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it," <i>Proc. Natl. Acad. Sci., USA</i> , 84:2019-2023, 1987.
	C46	Hanley <i>et al.</i> , "Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes," <i>J. Virol.</i> , 76: 525-531, 2002.
	C47	Heinz <i>et al.</i> , In: <i>Virus Taxonomy</i> , Regenmortel <i>et al.</i> eds., 7 th International Committee for the Taxonomy of Viruses, p 859-878, Academic Press, San Diego, 2000.
	C48	Hilton <i>et al.</i> , "Saturation mutagenesis of the WSXWS motif of the erythropoietin receptor." <i>J. Biol. Chem.</i> , 271(9):4699-4708, 1996.
	C49	Huang <i>et al.</i> , "Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus," <i>J. Virology</i> , 79: 7300-7310, 2005.
	C50	Jackson <i>et al.</i> , "Isolation of Arabidopsis mutants altered in the light-regulation of chalcone synthase gene expression using a transgenic screening approach." <i>Plant J.</i> , 8:369-380, 1995.
	C51	Jayasena, "Aptamers: an emerging class of molecules that rival antibodies in diagnostics," <i>Clinical Chemistry</i> , 45:1628-1650, 1999.
	C52	Jia <i>et al.</i> , "Genetic analysis of West Nile New York 1999 encephalitis virus." <i>Lancet</i> , 354:1971-1972, 1999.
	C53	Jones <i>et al.</i> , "Flavivirus Capsid Is a Dimeric Alpha-Helical Protein," <i>J. Virology</i> , 77: 7143-7149, 2003.
	C54	Kofler <i>et al.</i> , "Mimicking live flavivirus immunization with a noninfectious RNA vaccine," <i>PNAS</i> , 101(7): 1951-1956, 2004.

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C55	Kunsch <i>et al.</i> , "Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation," <i>Molecular and Cellular Biology</i> , 12:4412-4421, 1992.
	C56	Lanciotti and Kerst, "Nucleic Acid Sequence-Based Amplification Assays for Rapid Detection of West Nile and St. Louis Encephalitis Viruses," <i>J. Clinical Microbiology</i> , 39(12): 4506-4513, 2001.
	C57	Lanciotti <i>et al.</i> , "Complete Genome Sequences and Phylogenetic Analysis of West Nile Virus Strains Isolated from the United States, Europe, and the Middle East," <i>Virology</i> , 298: 96-105, 2002.
	C58	Lanciotti <i>et al.</i> , "Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States." <i>Science</i> , 286(5448):2333-2337, 1999.
	C59	Lee <i>et al.</i> , "Common E Protein Determinants for Attenuation of Glycosaminoglycan-Binding Variants of Japanese Encephalitis and West Nile Viruses," <i>J. Virology</i> , 78(15): 8271-8280, 2004.
	C60	Lescaer <i>et al.</i> , "The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH," <i>Cell</i> , 105:137-148, 2001.
	C61	Lustig <i>et al.</i> , "A Live Attenuated West Nile Virus Strain as a Potential Veterinary Vaccine," <i>Viral Immunology</i> , 13(4): 401-410, 2000.
	C62	Ma <i>et al.</i> , "Solution structure of dengue virus capsid protein reveals another fold," <i>PNAS</i> , 101(10): 3414-3419, 2004.
	C63	Mandl <i>et al.</i> , "Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site." <i>J. Virol</i> , 74(20):9601-9609, 2000.
	C64	Marshall <i>et al.</i> , "Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytide," <i>PNAS</i> , 89:6265-6269, 1992.
	C65	Martin <i>et al.</i> , "Molecular basis of mitomycin C resistance in streptomycetes: structure and function of the MRD protein." <i>Structure</i> , 10:933-942, 2002.
	C66	Mashimo <i>et al.</i> , "A nonsense mutation in the gene encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice," <i>PNAS</i> , 99(17): 11311-11316, 2002
	C67	McMinn, "The molecular basis of virulence of the encephalitogenic flaviviruses," <i>J. General Virology</i> , 78: 2711-2722, 1997.

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C68	Miller <i>et al.</i> , "Allele-specific silencing of dominant disease genes," <i>PNAS</i> , 100:7195-7200, 2003.
	C69	Monath <i>et al.</i> , "West Nile Virus Vaccine," <i>Current Drug Targets</i> , 1: 37-50, 2001.
	C70	<i>Morbidity and Mortality Weekly Report</i> , 51(36):805-824, 2002.
	C71	<i>Morbidity and Mortality Weekly Report</i> , 51(38):862-864, 2002.
	C72	Murgue <i>et al.</i> , "The ecology and epidemiology of West Nile virus in Africa, Europe and Asia." <i>Curr Top Microbiol Immunol</i> , 267:195-221, 2002.
	C73	Murthy <i>et al.</i> , "Crystal Structure of Dengue Virus NS3 Protease in Complex with a Bowman-Birk Inhibitor: Implications for Flaviviral Polypeptide Processing and Drug Design," <i>J. Mol. Biol.</i> , 301: 759-767, 2000.
	C74	Murthy <i>et al.</i> , "Dengue Virus NS3 Serine Protease," <i>J. Biol. Chem.</i> , 274(9): 5573-5580, 1999.
	C75	Mutebi <i>et al.</i> , "Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa." <i>J. Virol</i> , 75:6999-7008, 2001.
	C76	Nakamaye <i>et al.</i> , "Direct sequencing of polymerase chain reaction amplified DNA fragments through the incorporation of deoxynucleoside alpha-thiotriphosphates," <i>Nucleic Acids Research</i> , 16: 9947-59, 1988.
	C77	Niedrig <i>et al.</i> , "Comparison of six different commercial IgG-ELISA kits for the detection of TBEV-antibodies." <i>J Clinical Virology</i> , 20:179-182, 2001.
	C78	Papin <i>et al.</i> , "SYBR green-based real-time quantitative PCR assay for detection of West Nile Virus circumvents false-negative results due to strain variability," <i>J. Clin. Microbiol.</i> , 42:1511-1518, 2004.
	C79	Pletnev <i>et al.</i> , "West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy," <i>PNAS</i> , 99(5): 3036-3041, 2002.
	C80	Quirin <i>et al.</i> , "West Nile virus, Guadeloupe," <i>Emerg. Infect. Dis.</i> , 10: 706-708, 2004.
	C81	Rey <i>et al.</i> , "Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein." <i>Nature</i> , 375:291-298, 1995.

25526940 1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C82	Rey <i>et al.</i> , "The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution," <i>Nature</i> , 375:291-298, 1995.
	C83	Ryan <i>et al.</i> , "Virus-encoded proteinases of the <i>Flaviviridae</i> ," <i>J. General Virology</i> , 79: 947-959, 1998
	C84	Sanchez and Ruiz, "A single nucleotide change in the E protein gene of dengue virus 2 Mexican strain affects neurovirulence in mice." <i>J Gen Virol</i> , 77(Pt 10):2541-2545, 1996.
	C85	Sazani <i>et al.</i> , "Nuclear antisense effects of neutral anionic and cationic oligonucleotide analogs," <i>Nucleic Acids Research</i> , 29:3965-3974, 2001.
	C86	Scherret <i>et al.</i> , "Biological significance of glycosylation of the envelope protein of Kunjin virus." <i>Ann NY Acad Sci</i> , 951:361-363, 2001.
	C87	Semizarov <i>et al.</i> , "Specificity of short interfering RNA determined through gene expression signatures," <i>PNAS</i> , 100:6347-52, 2003.
	C88	Short <i>et al.</i> , "Contribution of antibody heavy chain CDR1 to digoxin binding analyzed by random mutagenesis of phage-displayed Fab 26-10," <i>J. Biol. Chem.</i> , 270:28541-50 1995.
	C89	Shrestha <i>et al.</i> , "Infection and Injury of Neurons by West Nile Encephalitis Virus," <i>J. Virology</i> , 77(24): 13203-13213, 2003.
	C90	Smith <i>et al.</i> , "Sensitivity and specificity of photoaptamer probes," <i>Molecular & Cellular Proteomics</i> , 2:11-18, 2003.
	C91	Song <i>et al.</i> , "Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages," <i>J. Virol.</i> , 77:7174-81, 2003.
	C92	Tesh <i>et al.</i> , "Experimental yellow fever virus infection in the Golden Hamster (<i>Mesocricetus auratus</i>). 1. Virologic, biochemical, and immunologic studies." <i>J. Infect Dis.</i> , 183:1431-1436, 2001.
	C93	Ueda <i>et al.</i> , "Phosphorothioate-containing RNAs show mRNA activity in the prokaryotic translation systems in vitro," <i>Nucleic Acids Research</i> , 19:547-552, 1991.
	C94	van der Meulen <i>et al.</i> , "West Nile virus in the vertebrate world," <i>Arch. Virol.</i> , 150: 637-657, 2005.
	C95	Volk <i>et al.</i> , "Solution Structure and Antibody Binding Studies of the Envelope Protein Domain III from the New York strain of West Nile Virus," <i>JBC Papers in Press</i> , published on June 9, 2004 as Manuscript M402385200.

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C96	Warren <i>et al.</i> , "A rapid screen of active site mutants in glycinamide ribonucleotide transformylase." <i>Biochemistry</i> , 35(27):8855-8862, 1996.
	C97	Whitehead <i>et al.</i> , "A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys," <i>Journal of Virology</i> , 77:1653-1657, 2003.
	C98	Wong <i>et al.</i> , "Directed mutagenesis of the Rhodobacter capsulatus puhA gene and orf 214: pleiotropic effects on photosynthetic reaction center and light-harvesting 1 complexes." <i>J. Bacteriol.</i> , 178(8):2334-2342, 1996.
	C99	Xie <i>et al.</i> , "Mutation in NSS protein attenuates mouse neurovirulence of yellow fever 17D vaccine virus," <i>J. General Virology</i> , 79: 1895-1899, 1998.
	C100	Yamshchikov <i>et al.</i> , "An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development," <i>Virology</i> , 330: 304-312, 2004.
	C101	Yamshchikov <i>et al.</i> , "An infectious clone of the West Nile flavivirus," <i>Virology</i> , 281: 294-304, 2001.
	C102	Yang <i>et al.</i> , "Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing," <i>Nucleic Acid Research</i> , 30:132-140, 2002.
	C103	Yang <i>et al.</i> , "Immunofluorescence assay and flow-cytometry selection of bead-bound aptamers," <i>Nucleic Acids Research</i> , 31:e54, 2003.
	C104	Yelton <i>et al.</i> , "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis." <i>J Immunol.</i> , 155(4):1994-2004, 1995.
	C105	Yokota <i>et al.</i> , "Inhibition of intracellular hepatitis C virus by synthetic and vector-derived small interfering RNAs," <i>EMBO Rep.</i> , 4:602-608, 2003.
	C106	Yoshii <i>et al.</i> , "Enzyme-linked immunosorbent assay using recombinant antigens expressed in mammalian cells for serodiagnosis of tick-borne encephalitis." <i>J Virol Methods</i> , 108:171-179, 2003.
	C107	Yu <i>et al.</i> , "Solution Structure and Structural Dynamics of Envelope Protein Domain III of Mosquito- and Tick- Borne Flaviviruses," <i>Biochemistry</i> , 43: 9168-9176, 2004.

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's		Applicant Alan Barrett <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 4, 2008	Group: 1648
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C108	Zanotto <i>et al.</i> , "An arbovirus cline across the northern hemisphere." <i>Virology</i> , 210:152-159, 1995.
	C109	Zeng <i>et al.</i> , "ATP-binding site of human brain hexokinase as studied by molecular modeling and site-directed mutagenesis." <i>Biochemistry</i> , 35(40):13157-13164, 1996.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

25526940 1

EXAMINER: /Stacy B. Chen/

DATE CONSIDERED: 03/01/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.